source
- FDA approves Infilbray, first therapy for neurological symptoms of Type 3 Gaucher diseaseThe U.S. Food and Drug Administration has approved Infilbray (venglustat) tablets for treating the neurological manifestations of Type 3 Gaucher disease in adults and children weighing at least 15…
- AI bio startup Boltz secures $110 million Series A as AI drug design platform usage surgesBoltz, an artificial‑intelligence driven biotech startup, announced a $110 million Series A financing round less than a year after emerging from stealth with an initial $28 million investment. The…